(±)5(6)-EET-d11 (Synonyms: (±)5,6-EET-d11) |
| رقم الكتالوجGC46262 |
A neuropeptide with diverse biological activities
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: N/A
Sample solution is provided at 25 µL, 10mM.
;)
_1-7.$$$37316672@70.jpg');)
;)
;)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
;)
;)
;)
_1124-1138.$$$35908550@30.jpg');)
_766-780.$$$37100057@30.jpg');)
_418-432.$$$36893736@30.jpg');)
_240-255.$$$35108512@29.jpg');)
_533-545.$$$36543525@28.jpg');)
_264-276.$$$36600053@22.jpg');)
_2214998.$$$@0.jpg');)
5(6)-EET-d11 is intended for use as an internal standard for the quantification of (±)5(6)-EET by GC- or LC-MS. 5(6)-EET is a fully racemic version of the enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes.1,2 In solution, 5(6)-EET degrades into 5,6-DiHET and 5(6)-δ-lactone, which can be converted to 5(6)-DiHET and quantified by GC-MS.3 In neuroendocrine cells, such as the anterior pituitary and pancreatic islets, 5(6)-EET has been implicated in the mobilization of calcium and hormone secretion.4,5 5(6)-EET is an inhibitor of T-type voltage-gated calcium channels (Cav3) that inhibits isoforms Cav3.1, Cav3.2 (IC50 = 0.54 µM), and Cav3.3 and decreases nifedipine-resistant phenylephrine-induced vasoconstriction in isolated mouse mesenteric arteries via Cav3.2 blockade when used at a concentration of 3 µM.6 In addition, it is a substrate of COX-1 and COX-2, as measured by oxygen consumption and product formation assays when used at a concentration of 50 µM.7 (±)5(6)-EET-d11 is provided as a mixture of the free acid and lactone.
1.Chacos, N., Falck, J.R., Wixtrom, C., et al.Novel epoxides formed during the liver cytochrome P-450 oxidation of arachidonic acidBiochem. Biophys. Res. Commun.104(3)916-922(1982) 2.Oliw, E.H., Guengerich, F.P., and Oates, J.A.Oxygenation of arachidonic acid by hepatic monooxygenases. Isolation and metabolism of four epoxide intermediatesJ. Biol. Chem.257(7)3771-3781(1982) 3.Rashid, M., Manivet, P., Nishio, H., et al.Identification of the binding sites and selectivity of sarpogrelate, a novel 5-HT2 antagonist, to human 5-HT2A, 5-HT2B and 5-HT2C receptor subtypes by molecular modelingLife Sci.73(2)193-207(2003) 4.Snyder, C., Lattanzio, F., Yadagiri, P., et al.5,6-Epoxyeicosatrienoic acid mobilizes Ca2+ in anterior pituitary cellsBiochem. Biophys. Res. Commun.139(3)1188-1194(1986) 5.Falck, J.R., Manna, S., Moltz, J., et al.Epoxyeicosatrienoic acids stimulate glucagon and insulin release from isolated rat pancreatic isletsBiochem. Biophys. Res. Commun.114(2)743-749(1983) 6.Cazade, M., Bidaud, I., Hansen, P.B., et al.5,6-EET potently inhibits T-type calcium channels: Implication in the regulation of the vascular tonePflugers Arch.466(9)1759-1768(2014) 7.Rand, A.A., Barnych, B., Morisseau, C., et al.Cyclooxygenase-derived proangiogenic metabolites of epoxyeicosatrienoic acidsProc. Natl. Acad. Sci. USA114(17)4370-4375(2017)
| Cas No. | N/A | SDF | |
| المرادفات | (±)5,6-EET-d11 | ||
| Canonical SMILES | [2H]C(C([2H])([2H])C([2H])([2H])[2H])([2H])C([2H])([2H])C([2H])([2H])/C=C\C/C=C\C/C=C\C[C@@H](O1)[C@@H]1CCCC(O)=O | ||
| Formula | C20H21D11O3 | M.Wt | 331.5 |
| الذوبان | DMF: 50 mg/ml,DMSO: 50 mg/ml,Ethanol: 50 mg/ml,PBS (pH 7.2): 1 mg/ml | Storage | Store at -80°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0166 mL | 15.083 mL | 30.1659 mL |
| 5 mM | 0.6033 mL | 3.0166 mL | 6.0332 mL |
| 10 mM | 0.3017 mL | 1.5083 mL | 3.0166 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 31 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *